《美股業績》AbbVie上調全年盈測 新療法銷售勁推高次季收入
艾伯維(AbbVie)(ABBV.US)周四上調年度利潤預期,因關節炎藥物修美樂(Humira)銷量跌幅低於預期,加上新療法銷售強勁,第二季度純利按年升119%至20.24億美元,調整後每股盈利為2.91美元,超過分析師平均預期的2.81美元。
期內,收入138.65億美元,按年跌4.9%。多種仿製藥進入美國市場後,修美樂全球銷售額按年暴跌25.2%至40.1億美元,高於預期的39.4億美元。
艾伯維預期,2023年調整後每股盈利由之前的10.57美元至10.97美元,上調至10.9美元至11.1美元。該股周四升逾5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.